CADTH | Evidence Driven
CADTH | Evidence Driven

Keytruda for Non-Small Cell Lung Cancer (Second Line or Beyond) – Details

Details

Files
Generic Name:
Pembrolizumab
Project Status:
Complete
Therapeutic Area:
Non-Small Cell Lung Cancer
Manufacturer:
Merck Canada Inc.
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0077-000
NOC Status at Filing:
Post NOC
Strength:
50mg vial
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer (Second Line or Beyond)
Funding Request:
For the treatment of patients with metastatic NSCLC whose tumours express PD-L1 (as determined by a validated test) and who have disease progression on or after platinum-containing chemotherapy. Funding is being requested for patients with a TPS (Tumour Proportion Score) of PD-L1 ≥1%.
Sponsor:
Merck Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Pembrolizumab (Keytruda) Non-Small Cell Lung Cancer – pERC Final Recommendation Final Recommendation November 3, 2016 View PDF
Pembrolizumab (Keytruda) Non-Small Cell Lung Cancer – Final Clinical Guidance Report Guidance Reports November 3, 2016 View PDF
Pembrolizumab (Keytruda) Non-Small Cell Lung Cancer – Final Economic Guidance Report Guidance Reports November 3, 2016 View PDF
Pembrolizumab (Keytruda) Non-Small Cell Lung Cancer – pERC Initial Recommendation Initial Recommendation September 1, 2016 View PDF
Pembrolizumab (Keytruda) Non-Small Cell Lung Cancer – PAG Feedback on Initial Recommendation Feedback November 3, 2016 View PDF
Pembrolizumab (Keytruda) Non-Small Cell Lung Cancer – Manufacturer Feedback on Initial Recommendation Feedback November 3, 2016 View PDF
Pembrolizumab (Keytruda) Non-Small Cell Lung Cancer – Patient Advocacy Group Feedback on Initial Recommendation Feedback November 3, 2016 View PDF
Pembrolizumab (Keytruda) Non-Small Cell Lung Cancer – Patient Advocacy Group COI Declarations COI Declarations November 3, 2016 View PDF
Pembrolizumab (Keytruda) Non-Small Cell Lung Cancer – Clinician Feedback on Initial Recommendation Feedback November 3, 2016 View PDF
Pembrolizumab (Keytruda) Non-Small Cell Lung Cancer – Clinician COI Declarations COI Declarations November 3, 2016 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : November 18, 2016